Mainz Biomed (MYNZ) Competitors $0.21 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends MYNZ vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ALVO, ACABW, ACABU, BFRIW, and BTMDWShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Alvotech (ALVO), Atlantic Coastal Acquisition Corp. II (ACABW), Atlantic Coastal Acquisition Corp. II (ACABU), Biofrontera (BFRIW), and biote (BTMDW). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Alvotech Atlantic Coastal Acquisition Corp. II Atlantic Coastal Acquisition Corp. II Biofrontera biote Mainz Biomed (NASDAQ:MYNZ) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment. Do analysts prefer MYNZ or ATNFW? Mainz Biomed presently has a consensus price target of $3.00, suggesting a potential upside of 1,345.78%. Given Mainz Biomed's stronger consensus rating and higher possible upside, research analysts plainly believe Mainz Biomed is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MYNZ or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media favor MYNZ or ATNFW? In the previous week, Mainz Biomed had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Mainz Biomed and 0 mentions for 180 Life Sciences. Mainz Biomed's average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Mainz Biomed Neutral 180 Life Sciences Neutral Which has higher valuation & earnings, MYNZ or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than Mainz Biomed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$900KN/A-$26.30M-$1.64-0.13180 Life SciencesN/AN/AN/AN/AN/A Does the MarketBeat Community believe in MYNZ or ATNFW? Mainz Biomed received 13 more outperform votes than 180 Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperformMainz BiomedOutperform Votes1376.47% Underperform Votes423.53% 180 Life SciencesN/AN/A SummaryMainz Biomed beats 180 Life Sciences on 6 of the 6 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$6.57B$5.21B$8.84BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-0.1311.12100.3917.88Price / SalesN/A356.531,229.0485.62Price / CashN/A53.8241.2636.92Price / Book0.7710.597.216.54Net Income-$26.30M$153.02M$119.72M$226.15M7 Day Performance-13.07%3.96%2.13%3.77%1 Month Performance-25.39%-6.72%-2.24%4.46%1 Year Performance-81.31%30.92%32.44%27.57% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.1513 of 5 stars$0.21flat$3.00+1,345.8%-81.8%$0.00$900,000.00-0.1330ATNFW180 Life SciencesN/A$0.01flatN/A+7.4%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AGap DownAEHAWAesther Healthcare AcquisitionN/A$0.04-20.6%N/A-15.0%$0.00N/A0.002AIMDWAinosN/A$0.03-47.5%N/AN/A$0.00$40,633.000.0040ALVOWAlvotechN/A$3.06-10.0%N/AN/A$0.00$391.87M0.004Gap DownALVOAlvotech2.131 of 5 stars$12.44+0.2%$18.00+44.7%+31.4%$0.00$93.38M-6.711,026ACABWAtlantic Coastal Acquisition Corp. IIN/A$0.08flatN/A+71.4%$0.00N/A0.004Gap DownACABUAtlantic Coastal Acquisition Corp. IIN/A$8.05-26.8%N/A-23.6%$0.00N/A0.004Gap DownBFRIWBiofronteraN/A$0.07+18.2%N/AN/A$0.00$35.24M0.0070BTMDWbioteN/A$0.50flatN/A-53.3%$0.00$193.06M0.00N/A Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYNZ) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
